Multiple primary cancer is a state of disease that developed more than two cancers in an individual, independently. Multiple primary malignant cancer is divided to synchronous and metachronous type depending on the interval between their diagnoses. Synchronous multiple cancer is diagnosed within an interval of six months and metachronous multiple cancer more than six months interval. As further advance in diagnostic techniques and treatment method bring about progressive increase in the number of individuals living in the 'cancer age' group. So, the population of patients with subsequent primary cancer will increase and after all the incidence of multiple primary cancer will be increased, gradually. Herein, we experienced a case of a 83-year-old male patient with metachronous triple primary cancer composed of gastric cancer, bladder cancer and lung cancer. We found the adenocarcinoma of stomach, transitional cell cancer of bladder and squamous cell carcinoma of lung. For its great rarity, we report this case with review of literatures about the history, criteria, incidence, site relationship and so on.
Adenocarcinoma ; Aged, 80 and over ; Carcinoma, Squamous Cell ; Diagnosis ; Humans ; Incidence ; Lung Neoplasms ; Lung* ; Male ; Stomach Neoplasms ; Stomach* ; Urinary Bladder Neoplasms ; Urinary Bladder*

Foreign body aspiration occurs rarely in adults. Aspiration of foreign bodies into tracheobronchial tree commonly occurs by accident, and in most cases they get removed without delay. Sometimes, however, small foreign bodies that lodge in the peripheral airway are often asymptomatic initially and become symptomatic several years later. In these cases, unless a clear history of an aspiration event is obtained, it is difficult to even consider the aspiration as a cause of pneumonia. Foreign bodies were most frequently located in right lower lobe and usually aspirated unilaterally. A review of recent literature reveals only a few case reports of unilaterally aspirated foreign body in adults. We are reporting an adult case of obstructive pneumonia due to foreign bodies (fish vertebrae) aspirated into both bronchi at least 5 month prior to his hospitalization into our institute. Removal of the endobronchial foreign bodies was successfully accomplished by flexible bronchoscopy. The patient did not experience any complication and the pneumonia was completely resolved after removal of foreign bodies.
Adult ; Bronchi* ; Bronchoscopy ; Foreign Bodies ; Hospitalization ; Humans ; Pneumonia* ; Spine*

Foreign body aspiration occurs rarely in adults. Aspiration of foreign bodies into tracheobronchial tree commonly occurs by accident, and in most cases they get removed without delay. Sometimes, however, small foreign bodies that lodge in the peripheral airway are often asymptomatic initially and become symptomatic several years later. In these cases, unless a clear history of an aspiration event is obtained, it is difficult to even consider the aspiration as a cause of pneumonia. Foreign bodies were most frequently located in right lower lobe and usually aspirated unilaterally. A review of recent literature reveals only a few case reports of unilaterally aspirated foreign body in adults. We are reporting an adult case of obstructive pneumonia due to foreign bodies (fish vertebrae) aspirated into both bronchi at least 5 month prior to his hospitalization into our institute. Removal of the endobronchial foreign bodies was successfully accomplished by flexible bronchoscopy. The patient did not experience any complication and the pneumonia was completely resolved after removal of foreign bodies.
Adult ; Bronchi* ; Bronchoscopy ; Foreign Bodies ; Hospitalization ; Humans ; Pneumonia* ; Spine*

OBJECTIVES: Unequal access to cancer clinical trials is an important issue, given the potential benefits of participation for cancer patients. We evaluated regional disparities in access to cancer clinical trials in Korea. METHODS: From the Ministry of Food and Drug Safety database, we extracted 2,465 records of all cancer clinical trials approved between January 2012 and April 2023. To measure disparities in cancer clinical trial access, we calculated the ratio of clinical trials open to non-capital areas relative to those open to capital areas. We then analyzed temporal trends in this ratio, which we termed the trial geographical equity index (TGEI). RESULTS: Disparities in access to cancer clinical trials, as indicated by the TGEI, did not significantly improve during the study period (regression coefficient, 0.002; p=0.59). However, for phase II/III trials sponsored by global pharmaceutical companies, the TGEI improved significantly (regression coefficient, 0.021; p<0.01). In contrast, the TGEI deteriorated for trials initiated by investigators or those testing domestically developed therapeutics (regression coefficient, -0.015; p=0.05). Furthermore, the increasing trend of TGEI for phase II/III trials sponsored by global companies began to reverse after 2019, coinciding with the outbreak of coronavirus disease 2019 (COVID-19). CONCLUSIONS Over the past decade, access to cancer clinical trials has improved in Korea, particularly for phase II/III trials evaluating therapeutics from global companies. However, this increase in accessibility has not extended to trials initiated by investigators or those assessing domestically developed therapeutics. Additionally, the impact of COVID-19 on disparities in clinical trial access should be closely monitored.

BACKGROUND: Nitrous oxide (N2O) is much cheaper than recently introduced volatile anesthetics such as sevoflurane and desflurane, and can reduce the consumption of these anesthetics. The use of N₂O is under current debate. The purpose of this study was to evaluate economic effect of 50% N₂O during sevoflurane anesthesia in Korea. METHODS: Seventy patients were randomly allocated to Group A or Group N. Anesthesia induction was performed using propofol, rocuronium, and 3–5% of sevoflurane with air (Group A) or 50% N2O (Group N). Fresh gas flow (FGF) was 6 L/min during induction, and 3 L/min for maintenance. Mean arterial pressure (MAP), heart rate (HR), bispectral index (BIS), and minimum alveolar concentration (MAC) were recorded. The consumption of sevoflurane was measured at every 10 minutes for the first 1 hour. The economic effect was analyzed based on the payment criterion of Korean National Health Insurance Service. RESULTS: MAP, HR, BIS, and MAC showed no differences between the two groups. The sevoflurane consumptions for the first 1 hour were 39.2 ± 6.3 ml in Group A and 29.2 ± 4.9 ml in Group N (P < 0.01); and the N₂O consumption was 93.7 ± 1.5 L in Group N. The total costs of inhaled anesthetics were 16,190 (14.8 USD) and 13,062 (12.0 USD) Korean won for the first 1 hour in Groups A and N, respectively. CONCLUSIONS: Use of 50% N₂O with 3 L/min FGF reduced the sevoflurane consumption by 25% and anesthetic cost by 20% for the first 1 hour.
Anesthesia* ; Anesthetics ; Arterial Pressure ; Cost-Benefit Analysis* ; Heart Rate ; Humans ; Korea ; National Health Programs ; Nitrous Oxide* ; Propofol

Purpose: Capmatinib, an oral MET kinase inhibitor, has demonstrated its efficacy against non–small cell lung cancer (NSCLC) with MET dysregulation. We investigated its clinical impact in advanced NSCLC with MET exon 14 skipping mutation (METex14) or gene amplification. Materials and Methods: Patients who participated in the screening of a phase II study of capmatinib for advanced NSCLC were enrolled in this study. MET gene copy number (GCN), protein expression, and METex14 were analyzed and the patients’ clinical outcome were retrospectively reviewed. Results: A total of 72 patients were included in this analysis (group A: GCN ≥ 10 or METex14, n=14; group B: others, n=58). Among them, 13 patients were treated with capmatinib (group A, n=8; group B, n=5), and the overall response rate was 50% for group A, and 0% for group B. In all patients, the median overall survival (OS) was 20.2 months (95% confidence interval [CI], 6.9 to not applicable [NA]) for group A, and 11.3 months (95% CI, 8.2 to 20.3) for group B (p=0.457). However, within group A, median OS was 21.5 months (95% CI, 20.8 to NA) for capmatinib-treated, and 7.5 months (95% CI, 3.2 to NA) for capmatinib-untreated patients (p=0.025). Among all capmatinib-untreated patients (n=59), group A showed a trend towards worse OS to group B (median OS, 7.5 months vs. 11.3 months; p=0.123). Conclusion Our data suggest that capmatinib is a new compelling treatment for NSCLC with MET GCN ≥ 10 or METex14 based on the improved survival within these patients.